Status:
RECRUITING
Prostate Medication, Metabolism and Gut Microbiota
Lead Sponsor:
Turku University Hospital
Conditions:
Prostatic Hyperplasia
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
PROMED is a prospective, single center translational multiple cohort study to investigate the association of prostate medication and gut microbiota. The main aim is to investigate how prostate hormona...
Detailed Description
Prostate cancer (PCa) is a significant health care system challenge. PCa is the most common male cancer in Finland and most western countries. Interestingly, although the incidence of indolent (latent...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form.
- Ability and stated willingness to comply with all study procedures and availability for the duration of the study.
Exclusion
- Any history of a fecal transplantation.
- Recent (within 3 months or still symptomatic) gastroenteritis.
- Antibiotic treatment within 3 months (expect for antibiotic prophylaxis related to prostate biopsies).
- Inability to comply with the protocol of unwillingness to participate in the study.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06001619
Start Date
December 1 2022
End Date
December 31 2026
Last Update
August 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, 20100
2
University of Turku
Turku, Finland, 20100